Merck (MRK) Q3 2024 earnings summary

Executive summary

• Achieved 3.8–4% organic group sales growth in Q3 2024, with all sectors contributing; Healthcare led with 6.2% organic sales growth, Electronics grew 2.4% organically, and Life Science returned to growth.

• EBITDA pre increased 11.9–16.9% to €1.618 billion, with margin expansion to 30.7%; EPS pre rose 11.1% to €2.30.

• Operating cash flow grew 16.2% year-over-year to €1,458 million, exceeding EBITDA pre growth.

• All business sectors achieved profitable growth, with Healthcare and Electronics driving acceleration in profitability.

• Significant events included the acquisition of Mirus Bio, Unity-SC, and the termination of the xevinapant program.

Financial highlights

• Net sales reached €5,266 million, up 1.8% year-over-year, with a -2% currency impact.

• EBITDA pre margin expanded to 30.7% from 27.9% in Q3 2023.

• EPS pre up 11.1% to €2.30; reported EPS up 9.4% to €1.86.

• Operating cash flow for the first nine months rose 22.9% year-over-year to €3,355 million.

• Net financial debt at €7,553 million as of September 30, 2024.

Outlook and guidance

• 2024 guidance confirmed: sales €20.7–22.1 billion, EBITDA pre €5.8–6.4 billion, EPS pre €8.20–9.30, with sales expected toward the lower end and EBITDA pre around the midpoint.

• Organic sales growth for 2024 expected between 2% and 5%; EBITDA pre organic growth of 4% to 10%.

• Life Science to end slightly above lower ends of sales/earnings corridors; Healthcare near midpoints; Electronics in lower half.

• Effective tax rate for FY 2024 expected at 21–23%.

• Operating cash flow anticipated in the upper half of €4.0–4.6 billion.